HDR Brachytherapy in the Management of High-Risk Prostate Cancer

Table 1

Prostate cancer risk groups.

Group	Criteria
Low risk	T1-T2a and PSA ≤ 10 ng/mL and Gleason score ≤ 6
Intermediate risk	T2b or PSA > 10 ≤ 20 ng/mL or Gleason score 7
High risk	≥T2c or PSA > 20 ng/mL or Gleason score ≥ 8